Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
BIO is priced at $379.82 right now, up 2.89% on the session. That puts its market value at $10.16B, 1448th largest among the 2132 stocks we cover.
The 52-week range is $236.73 to $396.23. Today's price is about 90% of the way from the low to the high. Holders are ahead 22.9% over twelve months, and up 29.9% across the last three months.
On the chart it holds above both the 50-day ($366.95) and 200-day ($308.11) moving averages; RSI is 54, and the last 30 sessions moved at roughly 29% annualized volatility.
Buyers are paying 46.3 times trailing earnings.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 2132 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BIO is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +1.0% | Bullish |
| Price vs 50-day average | +3.5% | Bullish |
| Price vs 200-day average | +23.3% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 54.0 | Bullish |
| MACD (12,26,9) | 1.53 | Bearish |
| Bollinger band position | 63% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 8:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 2,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$379.82 is the latest print for BIO, a move of +2.89% against yesterday's close of $369.14. Today's low and high so far: $363.96 and $381.78.
Equity value comes to $10.16B at the current price. By that measure it is number 1448 of the 2132 names in our coverage.
Buyers pay 46.3 times the last twelve months of profit (EPS $27.85).
The year's floor is $236.73 and the ceiling $396.23. Shares are 4.1% away from that ceiling.
Our data shows no dividend paid by Bio-Rad Laboratories over the trailing twelve months.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on BIO.